September 26, 2017, Vol 318, No. 12, Pages 1083-1198
Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award
Gregory W. Daniel, PhD, MPH; Monika Schneider, PhD; Mark B. McClellan, MD, PhD
JAMA. 2017;318(12):1103-1104. doi:10.1001/jama.2017.10164
This Viewpoint describes the Priority Antimicrobial Value and Entry (PAVE) award, which has been proposed to address the problem of antimicrobial-resistant infections using limited public funds to shift to value-based payment for new, high-priority antimicrobial drugs.